Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 2/20 | 0.49 |
| ▸ | FNTB | P49356 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334252 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2USP2TSHRALDH1A1NPSR1 | |
| SCHEMBL2327783 | 0.83 | ALDH1A1 (0.54) | USP2TSHRALDH1A1NPSR1FNTA | |
| SCHEMBL2327780 | 0.83 | ALDH1A1 (0.54) | USP2TSHRALDH1A1NPSR1FNTA | |
| SCHEMBL9827556 | 0.83 | GAA (0.51) | CA2CA1GAALMNA | |
| SCHEMBL2329890 | 0.83 | ALDH1A1 (0.56) | USP2TSHRALDH1A1NPSR1FNTA | |
| SCHEMBL2329886 | 0.83 | ALDH1A1 (0.56) | USP2TSHRALDH1A1NPSR1FNTA | |
| SCHEMBL31445139 | 0.83 | LMNA (0.54) | GAALMNA | |
| SCHEMBL2330092 | 0.82 | FPR1 (0.57) | USP2TSHRALDH1A1NPSR1FNTA | |
| SCHEMBL2334449 | 0.82 | FNTA (0.55) | USP2TSHRALDH1A1NPSR1FNTA | |
| SCHEMBL2330087 | 0.82 | FPR1 (0.57) | USP2TSHRALDH1A1NPSR1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356979-B1 | ANTI-WRINKLE AGENTS | POLA CHEM IND INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-3173063-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2017-05-31 | — | — | EP | disclosed |
| US-8835498-B2 | Anti-wrinkle agents | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-2356979-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | GLA, H1-4, H1-3 | SMN1; SMN2 711/4885USP2 2398/4885TSHR 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.